Mather Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Mather Group’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$40.2K	Buy	80 +7	+10%	+$3.7K	﹤0.01%	1228
2026 Q2	$39K	Hold	73	–	–	﹤0.01%	1166
2026 Q1	$38.1K	Buy	+73	New	+$34.9K	﹤0.01%	1119
2025 Q4	–	Sell	-73	Closed	-$33.3K	–	1250
2025 Q3	$33.3K	Buy	+73	New	+$27.2K	﹤0.01%	999
2025 Q2	–	Sell	-73	Closed	-$24.1K	–	1278
2025 Q1	$24.1K	Hold	73	–	–	﹤0.01%	1050
2024 Q4	$22.4K	Hold	73	–	–	﹤0.01%	1056
2024 Q3	$15.4K	Hold	73	–	–	﹤0.01%	1109
2024 Q2	$19.4K	Buy	+73	New	+$17.4K	﹤0.01%	1267

Other funds holding MDGL

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Bourgeon Capital Management Darien, Connecticut $696M AUM 39.92% 1-Year Est. Return

Shikiar Asset Management New York $398M AUM 33.64% 1-Year Est. Return

Stanley-Laman Group Berwyn, Pennsylvania $915M AUM 50.26% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

SGH

Sivik Global Healthcare Greenwich, Connecticut $175M AUM 28.78% 1-Year Est. Return

Mather Group's MDGL Position: Q3 2026 in Review

Mather Group increased its Madrigal Pharmaceuticals (MDGL) stake by 9.6% in Q3 2026, buying an estimated $3.7K and bringing the position to 80 shares worth $40.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1228.

Mather Group first reported a position in MDGL in Q2 2024 and has held it in 8 quarters since. 58 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

Mather Group held 80 shares of Madrigal Pharmaceuticals worth $40.2K as of Q3 2026.
Mather Group bought 7 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $3.7K.
Madrigal Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #1228 holding.
Mather Group first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
58 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.